Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 12 | 2024Lilly Loses Counterfeit Tirzepatide Lawsuit; EMA Finds No Link Between GLP-1RAs and Suicide Ideation; Diamyd Ph3 Recruitment UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Apr 11 | 2024Lipocine Ph2 Obesity Results; 89bio Enters Manufacturing PartnershipPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Apr 10 | 2024Novo Expands Ginkgo Partnership; Dexcom Integrates New Remote Care Platform; LIB Presents Ph3 PCSK9i Data at ACC 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 09 | 2024Lilly Initiates Third Ph3 Retatrutide T2DM Trial; Rezdiffra Now Available in the US; Galectin to Continue Belapectin MASH Development; Arrowhead Presents at ACC 2024; BI Initiates New Obesity TrialsPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Apr 08 | 2024ACC 2024: Novo, Roche/Alnylam, Esperion, Novartis, and Amarin Present New Data; Novo Resubmits Catalent Acquisition Application; AZ Initiates Ph2 Balcinrenone/Dapa Trial in CKD; Silence Publishes Ph1 Lp(a) Results; Teladoc CEO Steps DownPurchase Blast
$599
Posted in: Glucose Monitoring, Other Apr 04 | 2024Ascletis MASH Development Updates; Biolinq Raises $58M for Intradermal Glucose Sensor; Arrowhead Initiates Ph3 Plozasiran TrialsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, SGLT2i Apr 03 | 2024Clive Meanwell and Ian Reed Take on the Obesity Market; Novo Initiates Icodec Switching Trial; Mounjaro Faces Continued US Supply Constraints; Amarin’s Vazkepa Exclusivity ExtendedPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Apr 02 | 2024Biomea and Fractyl Q4 ’23 Earnings; Glucotrack Implantable CGM Update; Costco Weight Loss Program; D&D Fast Track Designation in MASH; New Aligos Ph2a MASH Trial; Sernova Cell Pouch UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 01 | 2024Zepbound Supply Constraints Observed; NeuroBo Completes Ph2a MASH Trial Enrollment; Galectin Q4 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Mar 28 | 2024FDA Approves Akebia’s Vadadustat; Inventiva and NeuroBo Q4 ’23 Earnings; Supersapiens to Relaunch in US; Sagimet MASH Development UpdatesPurchase Blast
$599
Posted in: GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Other Mar 27 | 2024Altimmune Q4 ’23 Earnings Update; Lilly Insulin Supply Shortage; 89bio Receives EMA PRIME Designation for MASH; Ypsomed Sells Needle and BGM Business; Thomas Danne Joins JDRFPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring Mar 26 | 2024Viking’s Momentum Continues with Ph1 Oral Obesity Win; Dexcom Faces Minor Setback in Abbott LitigationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Mar 25 | 2024Novo acquires Cardior Pharmaceuticals; Novo initiates Ph2 Dual Agonist Trials in T2DM and Obesity; Esperion CLEAR Outcomes Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Mar 22 | 2024Novo Initiates Additional Ph3 Cagrisema T2DM Trials; CLEAR Outcomes Approved by FDA and Received Positive CHMP OpinionPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Mar 21 | 2024Wegovy SELECT Label Analysis; CMS Opens Obesity CoveragePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Mar 21 | 2024Awiqli (QW Insulin Icodec) Receives Positive CHMP Opinion; Oprah TV Special Spotlights Zepbound and WegovyPurchase Blast
$599
Posted in: Other, SGLT2i Mar 19 | 2024Inventiva Interim Ph2a MASH Results; Madrigal Announces $600M Public Offering; 89bio Initiates Ph3 ENLIGHTEN-Fibrosis MASH TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Mar 18 | 2024Icodec up for CHMP Opinion; March CHMP Agenda; Galmed Granted MASH Combo Patent; Sequel’s twiist AID Receives 510(k) ClearancePurchase Blast
$599
Posted in: GLP-1RA, Other Mar 15 | 2024Rezdiffra Patient and HCP Websites Observed; Terns Q4 ‘23 EarningsPurchase Blast
$599
Posted in: Other Mar 14 | 2024Madrigal’s Resmetirom Approved as First Treatment for MASHPurchase Blast